Wegovy Tablets Vs Injections

If you have been struggling with your weight for years, trying every diet and exercise plan only to end up back where you started, you are not alone — and it is not a personal failure. Obesity is a complex, chronic medical condition, and in 2026 there are now more clinically proven options available in the UK than ever before, with Wegovy tablets being one of the most talked-about solutions for people who want lasting, medically supported weight loss.

Quick Summary

Wegovy contains semaglutide, a GLP-1 receptor agonist that works by reducing appetite, slowing gastric emptying, and helping you feel fuller for longer. Clinical evidence shows it can help patients lose an average of 15% of their body weight when combined with a reduced-calorie diet and increased physical activity.

• Wegovy is a prescription-only weight loss treatment containing semaglutide 2.4 mg
• It is available as a weekly injection in the UK, with oral tablet formulations under active development
• It is suitable for adults with a BMI of 30 or over, or 27 or over with a weight-related health condition
• The dose is gradually increased over 16 weeks to reduce side effects such as nausea
• It should always be used alongside dietary changes and increased physical activity for best results

Table of Contents

1. What Are Wegovy Tablets and How Do They Work?
2. Who Can Take Wegovy for Weight Loss in the UK?
3. The Wegovy Dose Escalation Schedule Explained
4. Common and Serious Side Effects of Wegovy
5. Wegovy vs Other Weight Loss Treatments Available in the UK
6. How to Get Wegovy Through a UK Pharmacy or Prescriber
7. Key Takeaways
8. When to Seek Professional Advice
9. FAQs

What Are Wegovy Tablets and How Do They Work?

Wegovy is a brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally developed to manage type 2 diabetes before researchers discovered its powerful impact on body weight. When people talk about Wegovy tablets in the UK, they are often referring to the broader semaglutide treatment category, though Wegovy is currently licensed as a once-weekly subcutaneous injection rather than a traditional oral tablet. That said, oral semaglutide formulations are an active and growing area of development, with significant clinical data emerging in 2026.

So how does it actually work in the body? Semaglutide mimics the action of the natural GLP-1 hormone, which is released in the gut after eating. It does several things at once: it signals to the brain that you are full, it slows down the rate at which food leaves the stomach, and it reduces the appeal of high-calorie foods by acting directly on appetite-regulating centres in the brain. This is not simply about willpower — it is a physiological intervention that addresses the hormonal drivers of hunger and overeating.

The STEP clinical trial programme, which enrolled over 4,500 participants across multiple countries, showed that patients using semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks when combined with lifestyle changes. That is a level of weight loss previously only seen with bariatric surgery, which is why this class of medication has genuinely changed the landscape of obesity treatment in the UK.

• Semaglutide activates GLP-1 receptors in the brain and gut
• It reduces appetite, food cravings, and caloric intake
• It slows gastric emptying, helping you feel full for longer after meals
• It works on the reward centres of the brain to reduce the desire for high-fat foods
• Clinical trials show up to 15% average body weight reduction over 68 weeks

Who Can Take Wegovy for Weight Loss in the UK?

Wegovy is a prescription-only medication in the UK, which means you cannot simply buy it over the counter. It is intended for adults who meet specific clinical criteria, and these criteria exist to ensure the treatment is both safe and appropriate for your individual circumstances. If you have been frustrated by diet after diet with little lasting success, understanding whether you qualify is the first important step.

According to NHS and MHRA guidance, Wegovy is indicated for adults with a body mass index (BMI) of 30 kg/m² or above, which is classified as obese. It is also licensed for adults with a BMI of 27 to 29.9 kg/m², which is classified as overweight, provided they have at least one weight-related comorbidity. These comorbidities include conditions such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease — all of which are common complications of excess body weight and all of which can be significantly improved through meaningful weight loss.

There are also exclusions. Wegovy is not recommended for people who are pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma, or people with multiple endocrine neoplasia type 2. People with a history of pancreatitis should also use it with caution, and it is not licensed for use in children under 18. Your prescriber will complete a thorough consultation to assess whether it is appropriate for you before issuing a prescription.

• BMI of 30 or above, or 27 or above with a weight-related health condition
• Must be used alongside dietary and lifestyle changes — not as a standalone treatment
• Not suitable during pregnancy, breastfeeding, or in children under 18
• Not recommended for people with a personal or family history of medullary thyroid carcinoma
• A full medical consultation is required before starting treatment

The Wegovy Dose Escalation Schedule Explained

One of the most common concerns people have when starting any new weight loss medication is the side effects — particularly nausea and vomiting. Wegovy's dose escalation schedule has been specifically designed to minimise these effects by introducing the drug gradually, giving your body time to adjust at each stage before the dose is increased further. This is not just a recommendation; it is a clinically designed protocol that significantly improves tolerability and long-term treatment success.

You begin at the lowest dose of 0.25 mg once weekly for the first four weeks. This is considered a starting dose and is not expected to produce significant weight loss at this stage — its primary purpose is tolerability. After four weeks, the dose increases to 0.5 mg weekly, then 1 mg, then 1.7 mg, and finally reaches the full maintenance dose of 2.4 mg once weekly at week 17. If you experience side effects that are difficult to manage at any point during the escalation, your prescriber may recommend staying at your current dose for a longer period before moving up.

It is important to administer Wegovy on the same day each week, and it can be taken at any time of day with or without food. The injection is typically given in the abdomen, thigh, or upper arm. Rotating injection sites helps to avoid skin irritation. For anyone who is anxious about self-injecting, healthcare teams routinely provide guidance and support, and many people find that the auto-injector pen makes the process much more straightforward than they initially anticipated.

Week	Dose	Purpose	Expected Side Effects
Weeks 1–4	0.25 mg once weekly	Initiation and tolerability	Mild nausea, fatigue
Weeks 5–8	0.5 mg once weekly	Dose escalation	Nausea, reduced appetite
Weeks 9–12	1 mg once weekly	Continued escalation	Nausea, bloating, constipation
Weeks 13–16	1.7 mg once weekly	Approaching maintenance	Usually improving tolerance
Week 17 onwards	2.4 mg once weekly	Maintenance dose	Side effects typically mild at this stage

Common and Serious Side Effects of Wegovy

Understanding potential side effects is essential before starting any prescription medication, and Wegovy is no exception. The good news is that the majority of side effects are gastrointestinal in nature, tend to be mild to moderate in severity, and typically improve as your body adjusts to the treatment — particularly during the early weeks of the escalation schedule described above. Knowing what to expect means you are less likely to stop treatment unnecessarily at the first sign of discomfort.

The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are reported by a significant proportion of participants in clinical trials but are most intense during the dose escalation phase. Eating smaller meals, avoiding high-fat or very spicy food, and staying well hydrated can all help to manage these symptoms. Some people also experience headache, fatigue, and dizziness in the first few weeks, which are generally short-lived.

Serious but less common side effects include acute pancreatitis, gallbladder problems such as gallstones, and hypoglycaemia — particularly in patients who are also taking medications for diabetes. There have also been questions raised about a potential link between semaglutide and thyroid tumours, based on rodent studies, although this has not been confirmed in human populations. You should seek immediate medical attention if you experience severe abdominal pain that does not resolve, jaundice, or symptoms of an allergic reaction such as swelling of the face or difficulty breathing.

• Most common: nausea, vomiting, constipation, diarrhoea, stomach cramps
• Usually worst during dose escalation and improve over time
• Eating smaller, lower-fat meals can help manage gastrointestinal effects
• Seek immediate help if you experience severe abdominal pain or signs of an allergic reaction
• Report any unusual thyroid symptoms such as a lump in the neck or persistent hoarseness

Wegovy vs Other Weight Loss Treatments Available in the UK

With so many weight loss options now available in the UK market, it can feel genuinely overwhelming trying to work out which treatment is right for you. Whether you are comparing prescription medications, over-the-counter options, or surgical routes, it helps to understand how Wegovy stacks up against the alternatives based on clinical evidence rather than marketing claims.

One of the most direct comparisons is with Mounjaro weight loss injections (tirzepatide), which acts on both GLP-1 and GIP receptors. Clinical head-to-head data suggests tirzepatide may produce even greater average weight loss than semaglutide, though both are effective and the right choice will depend on your individual health profile, prescriber recommendation, and cost considerations. Another widely used prescription option is orlistat, which works completely differently by blocking fat absorption in the gut. Orlistat is available over the counter as Orlos orlistat 60mg weight loss capsules, but the weight loss results tend to be more modest than those seen with semaglutide.

For those who prefer non-prescription support, products like XLS Medical Weight Loss Plus tablets offer a complementary approach by helping to reduce the absorption of dietary fat and carbohydrates. Similarly, XLS Medical Direct Fat Binder sachets can support a calorie-controlled diet. However, it is worth being clear: over-the-counter options are not equivalent to prescription GLP-1 therapy in terms of the magnitude of weight loss they can deliver.

• Wegovy (semaglutide 2.4 mg) — average 15% body weight loss over 68 weeks
• Mounjaro (tirzepatide) — dual GIP/GLP-1 action, may produce slightly greater weight loss
• Orlistat — fat absorption blocker, more modest results, available OTC at lower doses
• XLS Medical — over-the-counter fat/carbohydrate binding, suitable as dietary support
• Bariatric surgery — most effective but invasive, reserved for severe cases

How to Get Wegovy Through a UK Pharmacy or Prescriber

Many people find themselves stuck on NHS waiting lists or uncertain about how to access treatment quickly in 2026. The good news is that Wegovy can be accessed through a regulated private online pharmacy service, which offers the same level of clinical safety as a face-to-face GP appointment — with the added convenience of completing your consultation from home. The process typically involves an online medical assessment reviewed by a UK-registered prescriber, followed by a private prescription being issued if you are clinically suitable.

When accessing Wegovy through a private online pharmacy, you should always ensure the service is regulated by the Care Quality Commission (CQC) and that prescribers are registered with either the General Medical Council (GMC) or the General Pharmaceutical Council (GPhC). Dispensing pharmacies should display their GPhC registration number clearly. At Cured Pharmacy, our prescribing team includes GPhC-registered pharmacists who conduct thorough consultations to ensure every patient receives safe, appropriate, and personalised care.

You will be asked about your weight, height, medical history, current medications, and any relevant health conditions before any prescription is issued. Ongoing monitoring is also an important part of responsible treatment — your prescriber should review your progress, side effects, and blood pressure periodically. Treatment should be discontinued if you have not achieved a weight loss of at least 5% of your starting body weight after 12 weeks at the maintenance dose, in line with NICE guidance.

• Complete an online medical consultation with a GPhC or GMC-registered prescriber
• Disclose all current medications and relevant medical history honestly
• Ensure the pharmacy or clinic is CQC regulated and GPhC registered
• Expect a review at 12 weeks on the maintenance dose to assess progress
• Combine with dietary changes and physical activity for the best outcomes

Key Takeaways

• Wegovy contains semaglutide 2.4 mg and is one of the most clinically effective weight loss treatments currently available in the UK
• It works by mimicking the GLP-1 hormone to reduce appetite, slow digestion, and act on appetite-regulating areas of the brain
• The 16-week dose escalation schedule is designed to minimise side effects and improve long-term tolerability
• It is suitable for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, and requires a prescription
• Private online prescriptions are available through regulated UK pharmacies, offering a safe and convenient route to treatment

When to Seek Professional Advice

While Wegovy is well tolerated by most patients, there are specific situations in which you should seek medical advice promptly. If you experience severe or persistent abdominal pain, particularly if it radiates to your back, stop using Wegovy and seek medical attention immediately, as this could be a sign of pancreatitis. Similarly, if you develop yellowing of the skin or eyes, dark urine, or persistent upper-right abdominal pain, this may indicate a gallbladder problem and requires urgent assessment.

You should also contact a healthcare professional if you notice a lump or swelling in your neck, develop a hoarse voice that does not resolve, or experience difficulty swallowing — these could be symptoms that warrant thyroid evaluation. If you are diabetic and start experiencing symptoms of low blood sugar such as shakiness, confusion, or sweating, review your diabetes medications with your prescriber, as dose adjustments may be needed alongside Wegovy.

Finally, if your mental health changes after starting treatment — including low mood, suicidal thoughts, or increased anxiety — please speak to a healthcare professional without delay. Regular check-ins with your prescriber throughout your treatment journey are the best way to catch and address any concerns early.

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets typically begin to show noticeable weight loss effects within the first four to eight weeks of treatment, though the full effect builds over several months. Most clinical trials show meaningful weight reduction after 12 weeks, with maximum benefit seen around 68 weeks of consistent use.

Is Wegovy safe to use long term?

Wegovy is considered safe for long-term use in suitable patients when prescribed and monitored by a healthcare professional. The SELECT trial published in 2023 demonstrated cardiovascular safety benefits over more than three years, and it is currently approved in the UK for ongoing chronic weight management.

Can you take Wegovy tablets with other medications?

Wegovy tablets may interact with certain medications, particularly oral contraceptives and other drugs that are absorbed in the gut. You should always disclose your full medication list to your prescriber before starting treatment, as some combinations may require dose adjustments or careful monitoring.

What is the starting dose of Wegovy tablets?

The starting dose of Wegovy tablets is 0.25 mg once weekly for the first four weeks, which is a low introductory dose designed to minimise side effects. The dose is then increased gradually over a 16-week escalation period until reaching the maintenance dose of 2.4 mg once weekly.

Scientific References

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. STEP 1 Trial.
2. National Institute for Health and Care Excellence (NICE). Technology Appraisal TA875: Semaglutide for managing overweight and obesity. NICE, UK.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy (semaglutide) product information and UK licensing data. MHRA, UK.